- Home
- NCNA vs THAR Comparison
NCNA vs THAR Comparison
Compare NCNA & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- THAR
- Stock Information
- Founded
- NCNA 1997
- THAR 2017
- Country
- NCNA United Kingdom
- THAR United States
- Employees
- NCNA N/A
- THAR N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- THAR Health Care
- Exchange
- NCNA Nasdaq
- THAR Nasdaq
- Market Cap
- NCNA 4.5M
- THAR 4.0M
- IPO Year
- NCNA 2017
- THAR 2022
- Fundamental
- Price
- NCNA $0.80
- THAR $1.45
- Analyst Decision
- NCNA Buy
- THAR Strong Buy
- Analyst Count
- NCNA 2
- THAR 1
- Target Price
- NCNA $25.00
- THAR $17.00
- AVG Volume (30 Days)
- NCNA 39.0K
- THAR 60.9K
- Earning Date
- NCNA 03-19-2025
- THAR 05-08-2025
- Dividend Yield
- NCNA N/A
- THAR N/A
- EPS Growth
- NCNA N/A
- THAR N/A
- EPS
- NCNA N/A
- THAR N/A
- Revenue
- NCNA N/A
- THAR N/A
- Revenue This Year
- NCNA N/A
- THAR N/A
- Revenue Next Year
- NCNA N/A
- THAR N/A
- P/E Ratio
- NCNA N/A
- THAR N/A
- Revenue Growth
- NCNA N/A
- THAR N/A
- 52 Week Low
- NCNA $0.77
- THAR $1.28
- 52 Week High
- NCNA $10.79
- THAR $7.46
- Technical
- Relative Strength Index (RSI)
- NCNA 34.90
- THAR 35.72
- Support Level
- NCNA $0.79
- THAR $1.28
- Resistance Level
- NCNA $0.97
- THAR $1.65
- Average True Range (ATR)
- NCNA 0.08
- THAR 0.14
- MACD
- NCNA -0.01
- THAR -0.00
- Stochastic Oscillator
- NCNA 10.71
- THAR 28.24
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.